A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.
Impact
The bill mandates that the Prescription Drug Affordability Board identify specific drugs that pose affordability challenges, either due to excessive costs or substantial price increases. It sets forth procedures for conducting affordability reviews and recommends potential upper payment limits based on comprehensive evaluations. Furthermore, the board is required to report annually to the General Assembly on price trends and legislative recommendations to further enhance drug affordability across the state.
Summary
House File 2408 establishes a Prescription Drug Affordability Board aimed at overseeing the costs associated with prescription drugs to protect stakeholders within Iowa's healthcare system from excessive pricing. This board is designed to address the rising costs of essential medications that impact both state health plans and patients. The bill stipulates the board's composition, operational standards, and the mechanisms for conducting affordability reviews on certain drugs, ensuring that pricing data and decisions remain transparent and in the public interest.
Contention
Notably, the bill aims to establish a stakeholder council that comprises various representatives from pharmacies, healthcare providers, and manufacturers, ensuring comprehensive input on drug affordability challenges. However, the establishment of this council raises concerns about possible conflicts of interest, especially regarding the appointment of board members who must not have ties to drug manufacturers. This point has sparked debate among legislators regarding the effectiveness and impartiality of the board's recommendations and decisions, which could influence the availability and price of drugs in Iowa.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.